Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Atnahs Pharma Denmark ApS
APS
Active
CVR 36699051
Ørestads Boulevard 108, 2300
København S
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 2015 · 11 years old
— employees
Monitor
Share
Denmark
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Atnahs Pharma Denmark ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (1)
NB
Neeshe Bhikhubhai Williams
Management
Management
2025
Former (2)
JS
James Sang Bum Lee
Management
Management
2023 – 2025
LJ
Lisbet Johansen
Management
Management
2015 – 2016
Board of directors
Non-executive oversight
Name
Role
Member since
Current (3)
MM
Mohammad Muqtadir Samy
Chairman
Chairman
2026
TJ
Twan Johannes Anna Nouwen
Board of Directors
Board of Directors
2026
CM
Christoph Michael Habereder
Board of Directors
Board of Directors
2026
Former (11)
JC
James Charles Burt
Board of Directors
Board of Directors
2021 – 2025
AV
Amit Vijaykumar Patel
Chairman
Chairman
2016 – 2026
AT
Alastair Thomas Badgett Hay
Board of Directors
Board of Directors
2019 – 2021
RB
Rishi Bhikhu
Board of Directors
Board of Directors
2019 – 2022
ZJ
Zubair Javeed
Board of Directors
Board of Directors
2025 – 2025
MJ
Mark John Cotterill
Board of Directors
Board of Directors
2019 – 2019
DV
Dipen Vijaykumar Patel
Deputy Chairman
Deputy Chairman
2016 – 2019
JW
Jesper Wilhelm Voss
Board of Directors
Board of Directors
2021 – 2023
FA
Felipe Andres Florez Arango
Board of Directors
Board of Directors
2021 – 2023
AC
Anthony Charles Playle
Board of Directors
Board of Directors
2016 – 2020
SP
Santsagar Patel
Board of Directors
Board of Directors
2025 – 2026
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Atnahs Pharma UK Limited
Individual
100%
100%
2018
Svend Aage Johansen
Individual
33.33–49.99%
33.33–49.99%
2018
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Atnahs Pharma Denmark ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network